Fulcrum Therapeutics Inc (NASDAQ: FULC)’s stock price has gone decline by -9.19 in comparison to its previous close of 3.32, however, the company has experienced a -13.61% decrease in its stock price over the last five trading days. seekingalpha.com reported 2024-11-13 that Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir – President and Chief Executive Officer Alan Musso – Chief Financial Officer Iain Fraser – Senior Vice President, Early Development Patrick Horn – Chief Medical Officer Conference Call Participants Matthew Biegler – Oppenheimer Dae Gon Ha – Stifel Edward Tenthoff – Piper Sandler Rick Miller – Cantor Fitzgerald Greg Renza – RBC Capital Joori Park – Leerink Corinne Johnson – Goldman Sachs Operator Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Is It Worth Investing in Fulcrum Therapeutics Inc (NASDAQ: FULC) Right Now?
The stock has a 36-month beta value of 2.10. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FULC is 52.73M, and at present, short sellers hold a 9.43% of that float. On November 15, 2024, the average trading volume of FULC was 1.63M shares.
FULC’s Market Performance
FULC’s stock has seen a -13.61% decrease for the week, with a -15.07% drop in the past month and a -67.72% fall in the past quarter. The volatility ratio for the week is 7.74%, and the volatility levels for the past 30 days are at 5.78% for Fulcrum Therapeutics Inc The simple moving average for the past 20 days is -9.76% for FULC’s stock, with a -58.52% simple moving average for the past 200 days.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with H.C. Wainwright repeating the rating for FULC by listing it as a “Neutral.” The predicted price for FULC in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on September 13, 2024 of the current year 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to FULC, setting the target price at $4 in the report published on September 12th of the current year.
FULC Trading at -19.66% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.99% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 7.74%, as shares sank -13.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -64.29% lower at present.
During the last 5 trading sessions, FULC fell by -12.61%, which changed the moving average for the period of 200-days by -61.97% in comparison to the 20-day moving average, which settled at $3.34. In addition, Fulcrum Therapeutics Inc saw -55.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 236 shares at the price of $7.76 back on May 07 ’24. After this action, Tourangeau Greg now owns 11,571 shares of Fulcrum Therapeutics Inc, valued at $1,831 using the latest closing price.
Tourangeau Greg, the Vice President, Finance of Fulcrum Therapeutics Inc, sale 4,884 shares at $11.72 during a trade that took place back on Mar 08 ’24, which means that Tourangeau Greg is holding 11,807 shares at $57,219 based on the most recent closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -0.38 for the present operating margin
- 0.77 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -0.22. The total capital return value is set at -0.12. Equity return is now at value -6.99, with -6.42 for asset returns.
Based on Fulcrum Therapeutics Inc (FULC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -0.94. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -9.64.
Currently, EBITDA for the company is -108.49 million with net debt to EBITDA at 2.43. When we switch over and look at the enterprise to sales, we see a ratio of 1.56. The receivables turnover for the company is 22.12for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.44.
Conclusion
To sum up, Fulcrum Therapeutics Inc (FULC) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
